Qyuns Therapeutics Co., Ltd. Class H (2509) Price & Analysis

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, focuses on the research and development of biologic therapies for autoimmune and allergic diseases in the People's Republic of China. The company's lead product candidates include QX002N, an interleukin (IL)-17A inhibitor in Phase III clinical trial for the treatment of ankylosing spondylitis and lupus nephritis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra, which has completed Phase II clinical trial, to treat atopic dermatitis, prurigo nodularis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria (CSU), asthma, and chronic obstructive pulmonary disease (COPD). It also develops QX001S, an IL-12/IL-23p40 inhibitor in Phase III clinical trial for the treatment of psoriasis (Ps), and ulcerative colitis/Crohn's disease (CD); QX004N an IL-23p19 inhibitor in Phase II clinical trial to treat Ps and CD; QX006N, an IFNAR1-targeting mAb, which is in Phase Ib clinical trial, for the treatment of systemic lupus erythematosus; and QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin in Phase Ib clinical trial to treat moderate-to-severe asthma and COPD. In addition, the company is developing QX007N targeting IL-33 for the treatment of COPD and asthma; QX013N targeting c-kit to treat CSU; and QX010N, an IL-31R inhibitor for the treatment of pruritus. Further, it researches, develops, and produces pharmaceutical products; and provides technical consultation services. Qyuns Therapeutics Co., Ltd. was incorporated in 2015 and is headquartered in Taizhou, China.